Dengue virus [DENV] infection is one of the most prevalent diseases transmitted by mosquitoes in tropical and sub- tropical regions. It is considered to be the second-most infectious disease after COVID-19. Approximately 3.6 billion individuals, including over 50% of the global population, reside in regions characterized by a significant susceptibility to Dengue virus (DENV) infections. According to available data, the total number of DENV infections is estimated to be approximately 390 million, with approximately 96 million of these infections resulting in symptomatic manifestations. The infection is a harbinger of non-specific fever, acute febrile viral rash, debilitating headaches, and in extreme cases can cause various physiological afflictions that affects the liver, clotting system, complement mediated immune response, hematopoiesis and the vascular systems. Due to the severity and the illness being widely spread across the globe, vaccine research has been the priority to mitigate the negative effects of this disease. There are various types of vaccines that are being actively researched upon all across the world. The setbacks that have been occurring in vaccine development were mainly due to the occurrence of various serotypes and the problem with the virulence of the dengue virus. However, with the research going on about the virulent parts of the virus, an effective vaccine would come up that can hopefully help tackle the severity of dengue illness.